Strategic Data Partnership with GAP

IXICO plc

("IXICO", the "Company" or the "Group")

Strategic Partnership between IXICO and the Global Alzheimer's Platform Foundation (GAP)

Agreement provides full data rights to the Bio-Hermes-002 Study in Alzheimer's Disease (AD)

Deepens IXICO's platform capability and involvement in global AD consortium

22 July 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has deepened its existing collaboration with the Global Alzheimer's Platform Foundation® (GAP) through an agreement securing full data usage rights in GAP's landmark Bio-Hermes-002 study.

GAP's Bio-Hermes-002 is one of the most prominent global studies in AD research, which aims to enhance the understanding of newly identified AD biomarkers and advance the regulatory acceptance of those biomarkers for use in clinical trials. IXICO is working closely with GAP and other biopharmaceutical companies engaged in Bio-Hermes-002, using its unique AI-driven platform and expertise, to assist with the neuroimaging analysis of the Bio-Hermes-002 study data. IXICO's participation in the trial further establishes it as a consortium partner of leading biopharmaceutical players jointly combatting AD.

Under the agreement, IXICO will pay GAP in a combination of cash and analysis services to GAP for the data usage rights. The board expects a strong return on this investment, as data from Bio-Hermes-002 will enable IXICO to:

· directly accelerate its market differentiating vascular biomarker analysis R&D program in AD and adjacent neurodegenerative diseases;

· extend its product offering to support blood-based biomarker market approval and use in AD; and

· deepen its relationship with GAP and engage directly with leading biopharmaceutical companies in the AD space.

Bram Goorden, CEO of IXICO, commented: "This official partnership strengthens the deep collaboration between IXICO and GAP. Working with GAP and the consortia partners is very rewarding clinically, and it is also particularly important for two strategic reasons. Firstly, it confirms IXICO's leading role in the AD research ecosystem, a key element in driving continued commercial opportunities. Secondly, the unique study data enables us to further develop highly differentiated neuroimaging biomarker technologies that advance the understanding, diagnosis and treatment for patients suffering from AD."

John Dwyer, President and CEO of GAP, commented: "GAP is proud to partner again with IXICO on the Bio-Hermes-002 study. Together, we're working to advance clinical trial design for Alzheimer's and related dementias by using cutting-edge technology to better detect disease pathology. IXICO's expertise brings valuable precision to this global effort at a critical time for the field."

Ends

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

About the Bio-Hermes-002 study: 

The Bio-Hermes-002 study is the second blood-based and digital biomarker study in partnership with the Global Alzheimer's Platform Foundation®. Bio-Hermes-002 builds on the success of Bio-Hermes-001, the first-of-its-kind study comparing blood-based biomarkers, digital cognitive tests, retinal exams, and speech analytics to traditional methods of measuring cognition including beta-amyloid positron emission tomography (PET) scans, the gold standard for measuring Alzheimer's disease (AD) pathology. The research study seeks volunteers with or without memory concerns to help identify new blood or digital tests that can help predict the presence of amyloid plaques and neurofibrillary tangles in the brain, which are the hallmarks of Alzheimer's disease. 

About the Global Alzheimer's Platform Foundation (GAP) www.globalalzplatform.org

The nonprofit Global Alzheimer's Platform Foundation was founded to speed the delivery of Alzheimer's treatments with a commitment to lowering the cost and improving the efficacy of ADRD clinical trials to ensure that treatments and therapies work for everyone. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting inclusivity in research studies, and celebrating the citizen scientists who make research possible.

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.